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Word count 2927 
Abstract: 
Background: The impact of intraocular involvement (IOL) in primary CNS lymphoma (PCNSL) has 
not been sufficiently evaluated. Here, we present the analysis of IOL in the only randomized phase III 
trial in PCNSL. Methods: The G-PCNSL-SG1 study evaluated the role of whole-brain radiotherapy in 
primary therapy of PCNSL. Data of the 526 eligible study patients were checked, and clinical 
characteristics, therapy and outcome of patients with IOL diagnosed at study inclusion were analyzed. 
Results: Ophthalmologic examination at study inclusion was performed in 297 patients (56.5%) of 
whom IOL was diagnosed in 19 (6.4%). Clinical characteristics did not significantly differ between 
patients with IOL (IOL+) and those without (IOL-). The median progression-free survival (PFS) in the 
IOL+ group was 3.5 months (95% CI 0.0-7.07) as compared to 8.3 months (95% CI 4.78-11.78) in the 
IOL- group (P = 0.004), the median overall survival (OS) was 13.2 months (95% CI 0.86-25.62) and 
20.5 months (95% CI 15.56-25.5), respectively (P = 0.155). In multivariate analysis, a significantly 
inferior PFS and OS for IOL+ patients were found.  
Conclusions: IOL at diagnosis of PCNSL was an independent negative prognostic indicator for PFS 
and OS in this analysis. 
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Introduction 
Primary CNS lymphoma (PCNSL) usually presents as an intracerebral mass but may also show 
concomitant meningeal or intraocular dissemination
1
. Intraocular involvement (IOL) of PCNSL is a 
rare condition, which may occur before PCNSL is diagnosed, concomitantly with the PCNSL 
diagnosis, or at relapse. The localization may include vitreous, retina or optic nerve head. The 
spectrum of clinical symptoms varies from asymptomatic patients (up to 40%) to symptoms of chronic 
uveitis masquerade syndrome such as blurred vision and floaters up to complaints of red eye, 
photophobia, and ocular pain
2-5
. Bilateral involvement is common and occurs in almost 80% of cases
2
. 
The diagnosis is made by ophthalmologic examination where typically vitreitis or multifocal yellow-
coloured subretinal infiltrates are seen. The cytologic confirmation in the vitreous is often confounded 
by the presence of reactive immune cells, necrotic cells, debris, and fibrin. In cytologically negative 
cases, chorioretinal biopsy can be performed at specialized centers, revealing tumor cell infiltrates 
between the retinal pigment epithelium and Bruch’s membrane, perivascular clumps of tumor cells in 
the retina and optic nerve head, diffuse infiltration in the vitreous, and hemorrhagic retinal necrosis
6
. 
Due to the extreme rarity of this condition, data on therapy and prognostic impact of IOL diagnosed 
concomitantly with PCNSL is very scarce. As a consequence the optimal therapy for IOL has not been 
established. Systemic chemotherapy with high-dose methotrexate (HDMTX) sometimes amended by 
ocular radiotherapy or ocular chemotherapy or rituximab instillation is currently being performed at 
most centers. The prognostic impact of IOL has not been sufficiently evaluated either. A few small 
and retrospective studies with heterogeneous treatment protocols failed to observe a significant 
difference in outcome of patients with IOL (IOL+) versus those without (IOL-)
7-9
. In the present 
analysis, we evaluate the impact of IOL on outcome of PCNSL patients treated within the G-PCNSL-
SG1 trial
10
.   
 
Methods: 
Patients and treatment  
As previously reported
10
, 526 eligible patients with newly diagnosed PCNSL were enrolled at 75 
centers and treated between May 2000 and May 2009. Major inclusion criteria were: 
immunocompetent adult patients with histologically or cytologically (in cerebrosponal fluid (CSF)) 
confirmed PCNSL, Karnofsky performance score (KPS) >30 when due to PCNSL or >50 when due to 
other conditions, creatinine clearence ≥50 ml/min and written informed consent. Clinical staging 
work-up included physical examination, mini mental status examination, biochemical serum profile, 
serological assessment for HIV and hepatitis B and C infection, brain MRI (CT when MRI was not 
available or possible), CT scans of chest and abdomen, bone marrow biopsy and CSF examination. 
Ophthalmologic assessment including slit-lamp examination was part of the staging work-up. Patients 
without initial slit-lamp examination were not excluded from trial participation. Patients were 
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 4 
randomly allocated to receive first-line chemotherapy based on HDMTX with or without subsequent 
whole-brain radiotherapy (WBRT), with stratification by age (<60 versus ≥60 years) and institution 
(Berlin versus Tübingen versus all other sites). Between May 2000 and August 2006, study therapy 
consisted of HDMTX (4 g/m
2
 as a 4-h i.v. infusion with dose reduction according to creatinine 
clearence) on day 1 of six 14-day cycles; thereafter, patients were to receive HDMTX plus ifosfamide 
1.5 g/m
2
  on days 3–5 of six 14-day cycles. Addition of ifosfamide was a protocol amendment based 
on increasing awareness that HDMTX alone might be an insufficient first-line chemotherapy. In those 
assigned to receive first-line chemotherapy followed by radiotherapy, WBRT was to be given at a total 
dose of 45 Gy in 1.5 Gy fractions. Patients within the WBRT randomization group who had ocular 
involvement at study inclusion were to receive WBRT with inclusion of both orbits up to 30 Gy. 
Patients allocated to first-line chemotherapy without WBRT who had not achieved complete response 
(CR) were given high-dose cytarabine (HDAraC), 2 × 3 g/m
2
 on days 1–2 of 22-day cycles, and did 
not receive any further eye-dedicated therapy.  
The study protocol was approved by local institutional review boards or ethical review committees. 
All participants gave written informed consent. 
 
Statistics  
For statistical analysis, patient pre-therapeutic characteristics were grouped according to prognostic 
factors previously published: age, Karnofsky Performance Score (KPS), the Memorial Sloan-Kettering 
Cancer Center (MSKCC) prognostic score (class 1 patients <50 years, class 2 patients ≥50 and KPS ≥ 
70, class 3 patients ≥50 and KPS < 70)9, lactate dehydrogenase (LDH) in serum, number of brain 
lesions (0–1 and ≥2). The tests of significance were carried out between IOL+ and IOL- patients. 
Progression-free survival (PFS) was defined as the time from study entry to first progression or death 
from any cause. Overall survival (OS) was defined as the time from study entry to death. PFS and OS 
were estimated by the Kaplan–Meier method. Group comparisons were carried out using the log-rank 
test. Distribution of patients’ characteristics to different groups was analyzed by the chi-square test. 
Mean values of independent groups were compared with Student’s t-test. The level of significance was 
0.05 (two-sided). In the multivariate analysis backward variable selection was applied. Two-sided 
95% confidence intervals are presented. Commercially available software was used (SPSS for 
Window, release 18.0). 
 
 
Results 
Patient characteristics  
Of 526 eligible patients, 297 (56.5%) underwent ophthalmologic assessment within initial staging 
work-up. Among them, 19 patients (6.4%) had concomitant IOL on the slit-lamp examination. In 9 of 
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 5 
these patients, IOL was further analyzed by cytomorphologic examination of vitreous aspirate with 
evidence of lymphoma cells in 8 patients and suspicious but inconclusive cytology in 1 patient. The 
main characteristics of IOL+ patients and the comparison with IOL- and all eligible study patients are 
summarized in Table 1. The comparison with patients without slit-lamp examination is given in 
Supplementary Table 1. No significant differences between these groups were observed for any 
parameter.  
 
Treatment and response  
Of the 19 IOL+ patients, 14 (73.7%) were treated with HDMTX monotherapy and 5 additionally 
received ifosfamide (Table 2). After HDMTX-based treatment 4 patients (21%) were in CR and did 
not receive further treatment. Fifteen patients failed to achieve CR: 4 (21%) had partial remission, one 
patient had stable disease, 9 (47%) had progressive disease and one patient had an unknown remission 
status (Table 2). The differences with respect to first-line chemotherapy and response between IOL+ 
and IOL- patients were not significant. Among patients who failed to achieve a CR to HDMTX-based 
treatment, 7 received WBRT (5 with ocular radiotherapy [RT]), 3 HDAraC, and 5 had a rapid 
progressive disease with poor performance status that excluded further treatments. After the total 
primary treatment 8 (42%) of 19 IOL+ patients achieved an objective response, which was complete in 
7 cases (37%).  
Salvage treatment was not part of the study treatment. In the IOL+ group, two patients received 
systemic chemotherapy and 5 patients received systemic chemotherapy (one with additional 
intravitreal injection of MTX) plus WBRT (two with ocular radiotherapy (RT)). All patients treated 
with salvage WBRT had not received WBRT as part of initial treatment and were thus not irradiated 
twice. 
 
Survival outcome  
The median follow-up of all patients who underwent ophthalmologic assessment was 78.4 months. 
The median PFS (Table 2 and Figure 1) in the IOL+ group was 3.5 months (95% CI 0.0-7.07), as 
compared to 8.3 months (95% CI 4.78-11.78) in the IOL- group (P = 0.004). Sites of progression or 
first relapse in IOL+ patients included brain in 12 patients (63%), eyes in 1 (5%), brain and eyes in 1 
(5%), meninges in 1 (5%) and was undetermined in 4 (21%). Both ocular relapses occurred within two 
months after completion of HDMTX-based chemotherapy. One patient showed an isolated intraocular 
relapse after an initial CR, the second patient had a partial response  and rapidly progressed with 
concomitant intracerebral and intraocular involvement. In the IOL- group, 8 (2.8%) patients relapsed 
with IOL. The median OS in the IOL+ group was 13.2 months (95% CI 0.86-25.62) versus 20.5 
months (95% CI 15.56-25.5) in the IOL- group (P = 0.155). In multivariate analyses, after adjustment 
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 6 
for age and KPS as the most important risk factors in PCNSL, we found a significantly inferior PFS 
(HR 2.18; P = 0.003) and OS (HR 2.17; P = 0.004) for IOL+ patients (Table 3). 
 
Discussion 
This is the first analysis of IOL in PCNSL in an adequately sized cohort treated within a prospective 
trial with HDMTX-based chemotherapy.  
The frequency of IOL in this study of 6.5% is within the range of 1-19% reported in prospective 
PCNSL patients` series
11-15
. The high range of IOL frequency reported is most probably due to a high 
proportion of asymptomatic patients and challenges in diagnosing this condition even for trained 
ophthalmologists. Efforts to improve the diagnostic accuracy include flow cytometry and 
determination of cytokine levels in the vitreous body
16,17
. However, these procedures are currently 
neither standardized nor commonly available for PCNSL staging.   
We did not observe any association between IOL and any other patients´ characteristics documented in 
the G-PCNSL-SG1. Particularly, there was no association with positive CSF cytology status that was 
previously described
7
. In fact, only one of our 19 IOL+ patients had concomitant meningeal 
dissemination, in contrast to 20 – 33% of IOL+ patients reported in the literature6,9. Moreover, we did 
not find serum LDH elevation more frequently in IOL+ patients
6
. 
This study is the first to demonstrate that IOL at diagnosis of PCNSL is an independent negative 
prognostic indicator both for PFS and OS. For PFS we found unambiguous results with relevant and 
significant hazard ratios both in univariate and multivariate analyses. For OS, after adjustment for KPS 
and age, we detected a significant hazard ratio of 2.2 in multivariate analysis for IOL+. The univariate 
analysis revealed a non-significant result which can be explained by a higher proportion of younger 
patients with better KPS in IOL+ as compared to IOL
-
. 
All previous analyses showing no prognostic impact of IOL in PCNSL were performed, as the present 
trial, in retrospectively analysed series, however, with more heterogeneously treated patients. In the 
three larger (n>10) series the outcome of IOL+ patients was comparable to that of IOL- and superior 
to that in the present study with median PFS of 18 months
2
 and median OS of 20-31 months
2,7,18
. This 
cannot be explained by differences in patients` age or performance status between those analyses and 
the present study. Moreover, HDMTX considered the most important treatment in PCNSL was given 
to all patients in our series but only to 55-84% of patients in the other series, whereas WBRT was part 
of treatment in 37% of our patients and 33-71% of patients in the other series, respectively. The 
frequency of ocular RT was, however, higher in the previous series with 45-64% as compared to 26% 
in our series, and it remains unclear if this has contributed to the better outcome.  
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 7 
IOL could reflect a higher tumor burden in PCNSL or a more aggressive tumor behaviour. Another 
hypothesis concerning the worse prognosis of IOL+ patients could be the involvement of a 
compartment that is difficult to treat. Previous analyses described difficulties in achieving therapeutic 
concentrations of MTX in the vitreous humor which may result in the development of a sanctuary 
from where surviving tumor cells may lead to a relapse. The higher rate of ocular relapse in IOL+ 
patients of 21-33%
2,7,18
 as compared to IOL- patients would support this hypothesis. The relatively low 
rate of ocular relapse found in the present series despite lower frequency of eye-dedicated treatment as 
compared to retrospective analyses
2,7,18
 could be explained by the lack of routine ophthalmologic 
examination during follow-up in the G-PCNSL-SG1 trial.  
Only 57% of patients from the G-PCNSL-SG1 study received an ophthalmologic evaluation which 
represents the major weakness of this analysis. Nevertheless, we do not think that our results were 
biased by patients` selection, since major clinical characteristics and outcome of patients who did not 
receive ophthalmologic examination were similar to those of examined patients (Table 1 and 
Supplementary Table 1).  
 
Our findings underline the importance of detailed ophthalmologic assessment even in asymptomatic 
PCNSL patients as recommended by the guidelines of the International Primary CNS Lymphoma 
Collaborative Group
21
, and suggest that these patients should be evaluated and treated as high-risk 
population. HDMTX alone might not be an appropriate treatment for these patients, and more 
aggressive therapy up to high-dose chemotherapy with stem-cell transplantation should be considered 
in those who can tolerate it. Whether an additional eye-dedicated treatment such as local RT or 
intravitreal injection of chemo-/immunotherapeutics
19,20
 can improve the prognosis of IOL+ PCNSL 
patients remains unclear
2
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Figure 1: Progression-free survival and overall survival in patients with intraocular 
involvement (IOL+) versus those without (IOL-). 
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Table 1: Comparison of clinical characteristics of patients with intraocular involvement (IOL+) 
versus those without (IOL-).  
 
Characteristics  IOL+ 
(n=19) 
n (%) 
 IOL-  
(n=278) 
n (%) 
 All patients 
(n=526) 
n (%)  
 
P  value 
(IOL+ versus 
IOL-) 
Age (years) 
Median (range) 
 
61 (46-76) 
 
64 (19-84) 
 
63 (19-84) 
 
0.279 
Male/female 14/5 153/125 299/227 0.152 
KPS, mean 74 70 70 0.477 
MSKCC score  
1 1 (5.3%) 42 (15.1%) 84 (15.9%) 0.284 
2 11 (57.9%) 126 (45.3%) 218 (41.4%)  
3 4 (21%) 88 (31.6%) 150 (28.5%)  
Not recorded 3 (15.8%) 22 (7.9%) 74 (14.0%)  
Serum LDH elevated 2 (10.5%) 69 (24.8%) 109 (20.7%) 0.1 
Not recorded 0 19 (6.8%) 229 (43.5%)  
Meningeal involvement 1 (5.2%) 7 (2.5%) 17 (3.2%) 0.403 
Not recorded 4 (21.0%) 49 (17.6%)  161 (30.6%)  
Number  of cerebral lesions  
0-1 7 (36.8%) 137 (49.3%) 262 (49.8%) 0.281 
≥2 lesions 8 (42.1%) 85 (30.6%) 169 (32.1%)  
Not recorded 4 (21.0%) 56 (20.1%) 95 (18.0%)  
KPS, Karnofsky Performance Score; MSKCC, Memorial Sloan-Kettering Cancer Center; LDH, lactate dehydrogenase 
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Table 2: Treatment, objective response to HDMTX-based chemotherapy and outcome of 
patients with intraocular involvement (IOL+) versus those without (IOL-). 
 
Characteristics IOL+ (n=19) 
n (%) 
IOL- (n=278) 
n (%) 
P value 
 
HDMTX versus 
HDMTX/IFO 
14 (73.7%) 
5 (26.3%) 
208 (74.8%) 
70 (25.2%) 
0.549 
WBRT 10 (52.6%) 140 (50.3%) 0.848 
Response to HDMTX-
based chemotherapy 
 
 
Complete response 4 (21.1%) 103 (37%) 0.289 
Partial response 4 (21.1%) 58 (20.9%)  
Stable disease 1 (5.2%) 12 (4.3%)  
Progressive disease 9 (47.4%) 74 (26.6%)  
Not recorded 1 (5.2%) 31 (11.1%)  
Median PFS (months) 3.5 (95% CI: 0.0-7.1) 8.3 (95% CI: 4.8-11.8) 0.004 
Median OS (months) 13.2 (95% CI: 0.9-25.6) 
20.5 (95% CI: 15.6-
25.5) 
0.155 
HDMTX, high-dose methotrexate; IFO, ifosfamide; WBRT, whole-brain radiotherapy; PFS, progression-free survival;  
OS, overall survival 
 
Table2
Table 3: Univariate and multivariate analyses for progression-free survival and overall 
survival.  
 Progression-free survival Overall survival 
 
Hazard 
ratio 
95% CI p value 
Hazard 
ratio 
95% CI p value 
Univariate analysis  
IOL+ 1.96 1.22-3.15 0.005 1.43 0.87-2.35 0.16 
age
*
 1.44 1.19-1.76 <0.001 2.00 1.61-2.49 <0.001 
sex
‡
 0.97 0.80-1.16 0.72 1.02 0.83-1.24 0.87 
KPS
†
 1.14 1.08-1.20 <0.001 1.19 1.12-1.25 <0.001 
LDH
#
 1.33 1.03-1.71 0.029 1.32 1.01-1.72 0.042 
Multivariate analysis  
IOL+ 2.18 1.30-3.66 0.003 2.17 1.29-3.66 0.004 
age
*
 not significant, p = 0.40 1.68 1.24-2.27 0.001 
sex
‡
 not significant, p = 0.99 not significant, p = 0.84 
KPS
†
 1.18 1.10-1.26 <0.001 1.20 1.12-1.29 <0.001 
LDH
#
 not significant, p = 0.057 not significant, p = 0.064 
*
Age of 60 years or older versus younger than 60 years. 
‡
Female sex versus male sex. 
†
10% decrease in 
Karnofsky Performance Score.  
#
Elevated serum lactate dehydrogenase (LDH) versus normal. 
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